Doc's Drug License Doomed: Expired State Permit Ends DEA Access
Published Date: 6/23/2025
Notice
Summary
Dr. William Thompson IV lost his DEA registration because he no longer has permission to handle controlled substances in California. He didn’t ask for a hearing, so the DEA officially revoked his registration as of late 2024. This means he can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Thompson
Dr. William Thompson IV's DEA Certificate of Registration No. FT3578082 is revoked effective July 23, 2025 because he is not licensed to practice medicine in California. As a result, he cannot legally prescribe, dispense, or handle controlled substances in California, which will affect his medical practice and any income tied to prescribing controlled drugs.
Pending Renewal and Application Denials
The DEA denied any pending applications by Dr. William Thompson IV to renew or modify Certificate of Registration No. FT3578082, as well as any other pending applications for additional registration in California. This prevents him from regaining DEA registration through those pending applications in California.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-11479 — Applications for New Awards; American History and Civics Education National Activities-Seminars for America's Semiquincentennial
The Department of Education is offering new grants for 2025 to support fun and educational seminars about American history and civics, celebrating the 250th anniversary of the United States. Schools, educators, and organizations can apply to get funding to create exciting learning experiences. This is a great chance to bring history to life with some extra cash and a clear deadline to join the celebration!
Next: 2025-11481 — Intent To Prepare the Bakersfield Field Office Oil and Gas Supplemental Environmental Impact Statement and Potential Resource Management Plan Amendment, California
The Bakersfield Field Office is updating its plan to manage oil and gas drilling on public lands in California. This means they’ll study how drilling affects the environment and might change rules to keep things safe and fair. Local communities, businesses, and nature lovers should get ready to share their thoughts soon, as this process will take some time and could impact future land use and jobs.